Charles River Laboratories International, Inc. (CRL)
NYSE · Healthcare
Charles River Laboratories International, Inc. Income Statement 2008–2025
| Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||||
| Revenue | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B | 1.36B | 1.30B | 1.17B | 1.13B | 1.14B | 1.13B | 1.17B | 1.30B |
| Gross Profit | — | — | — | — | — | — | — | — | 1.57B | 1.40B | 1.10B | 1.03B | 892.8M | 871.8M | 874.7M | 880.5M | 916.0M | 1.04B |
| Profitability | ||||||||||||||||||
| Operating Income | 25.2M | 227.3M | 617.3M | 651.0M | 589.9M | 432.7M | 351.2M | 331.4M | 288.3M | 237.6M | 206.4M | 177.7M | 151.4M | 165.8M | 174.3M | -298.5M | 169.6M | -451.8M |
| EBITDA | 428.5M | 589.1M | 931.4M | 954.8M | 855.4M | 667.7M | 549.2M | 493.2M | 419.4M | 364.2M | 301.3M | 274.1M | 248.0M | 247.0M | 259.5M | -204.9M | 259.6M | -365.0M |
| Net Income | -144.3M | 22.2M | 474.6M | 486.2M | 391.0M | 364.3M | 252.0M | 226.4M | 123.4M | 154.8M | 149.3M | 126.7M | 102.8M | — | — | -336.7M | 114.4M | -524.5M |
| Per Share Data | ||||||||||||||||||
| EPS (diluted) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding (dil.) | 50M | 52M | 51M | 51M | 51M | 51M | 50M | 49M | 49M | 48M | 48M | 48M | 48M | 48M | 51M | 63M | 66M | — |
Charles River Laboratories International, Inc. Income Statement — FAQ
Charles River Laboratories International, Inc. (CRL) income statement over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CRL's income statement history?
The chart and table above show Charles River Laboratories International, Inc.'s income statement by year and by quarter, including the growth rate.